Interpretation of BRCA2 Splicing Variants: A Case Series of Challenging Variant Interpretations and the Importance of Functional RNA Analysis.
BRCA2
Hereditary cancer syndromes
Pathogenicity
RNA analysis
Splice variants
Journal
Familial cancer
ISSN: 1573-7292
Titre abrégé: Fam Cancer
Pays: Netherlands
ID NLM: 100898211
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
08
06
2020
accepted:
15
12
2020
pubmed:
21
1
2021
medline:
5
3
2022
entrez:
20
1
2021
Statut:
ppublish
Résumé
A substantial proportion of pathogenic variants associated with an increased risk of hereditary cancer are sequence variants affecting RNA splicing. The classification of these variants can be complex when both non-functional and functional transcripts are produced from the variant allele. We present four BRCA2 splice site variants with complex variant interpretations (BRCA2 c.68-3T>G, c.68-2A>G, c.425G>T, c.8331+2T>C). Evidence supporting a pathogenic classification is available for each variant, including in silico models, absence in population databases, and published functional data. However, comprehensive RNA analysis showed that some functional transcript may be produced by each variant. BRCA2 c.68-3T>G results in a partial splice defect. For BRCA2 c.68-2A>G and c.425G>T, aberrant splicing was shown to produce a potentially functional, in-frame transcript. BRCA2 c.8331+2T>C may utilize a functional GC donor in place of the wild-type GT donor. The severity of cancer history for carriers of these variants was also assessed using a history weighting algorithm and was not consistent with pathogenic controls (carriers of known pathogenic variants in BRCA2). Due to the conflicting evidence, our laboratory classifies these BRCA2 variants as variants of uncertain significance. This highlights the importance of evaluating new and existing evidence to ensure accurate variant classification and appropriate patient care.
Identifiants
pubmed: 33469799
doi: 10.1007/s10689-020-00224-y
pii: 10.1007/s10689-020-00224-y
pmc: PMC8799590
doi:
Substances chimiques
BRCA1 Protein
0
BRCA2 Protein
0
BRCA2 protein, human
0
RNA Splice Sites
0
RNA, Messenger
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-19Informations de copyright
© 2021. The Author(s).
Références
Genet Med. 2020 Aug;22(8):1355-1365
pubmed: 32398771
Mol Cell. 2006 Jun 23;22(6):719-729
pubmed: 16793542
JAMA Netw Open. 2019 Oct 2;2(10):e1913900
pubmed: 31642931
PLoS Genet. 2017 Mar 24;13(3):e1006691
pubmed: 28339459
Blood. 2011 Sep 1;118(9):2430-42
pubmed: 21719596
Nucleic Acids Res. 2006;34(16):4630-41
pubmed: 16963498
Hum Mutat. 2019 Dec;40(12):2296-2317
pubmed: 31343793
Hum Mol Genet. 2016 May 15;25(10):1934-1945
pubmed: 26920070
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
JAMA. 2018 Sep 25;320(12):1266-1274
pubmed: 30264118
Hum Mutat. 2018 May;39(5):729-741
pubmed: 29460995
Cancers (Basel). 2019 Mar 01;11(3):
pubmed: 30832263
Hum Mutat. 2019 Oct;40(10):1856-1873
pubmed: 31131953
EMBO Rep. 2009 Sep;10(9):990-6
pubmed: 19609323
Cancer Res. 2020 Sep 1;80(17):3593-3605
pubmed: 32641407
Breast Cancer Res Treat. 2011 Oct;129(3):971-82
pubmed: 21638052
Breast Cancer Res Treat. 2014 Aug;147(1):119-32
pubmed: 25085752
Hered Cancer Clin Pract. 2019 May 22;17:14
pubmed: 31143303
Clin Sci (Lond). 2017 Mar 1;131(5):355-368
pubmed: 28202748
Front Genet. 2018 Sep 05;9:366
pubmed: 30233647
Front Oncol. 2018 May 03;8:140
pubmed: 29774201
Hum Mol Genet. 2016 Jun 1;25(11):2256-2268
pubmed: 27008870
Int J Cancer. 2019 Jul 15;145(2):401-414
pubmed: 30623411
Nucleic Acids Res. 2014;42(16):10564-78
pubmed: 25123659
Nucleic Acids Res. 2006;34(14):3955-67
pubmed: 16914448
Hum Mutat. 2018 Nov;39(11):1517-1524
pubmed: 30192042
NPJ Precis Oncol. 2020 Feb 24;4:4
pubmed: 32133419
J Med Genet. 2016 Aug;53(8):548-58
pubmed: 27060066
J Pathol. 2019 Aug;248(4):409-420
pubmed: 30883759
Eur J Hum Genet. 2017 Oct;25(10):1147-1154
pubmed: 28905878
Hum Mutat. 2019 Sep;40(9):1557-1578
pubmed: 31131967